Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cedar: Apatorsen + Gemcitabine/Carboplatin in Squamous NSCLC
NCT02423590Phase 2Unknown
- Sponsor
- Queen Mary University of London
- Start
- Jun 2014
- Primary completion
- May 2018
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of apatorsen in squamous cell carcinoma of the lung (LSCC), sponsored by Queen Mary University of London. Status: unknown.
02
Drugs
apatorsen
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT02423590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02423590.